Skip to main content
SpringerLink
Log in

Therapie des Morbus Paget mit dem Bisphosphonat Pamidronat (AHPrBP, früher APD)

Treatment of Paget's disease of bone using pamidronate

  • Originalien
  • Published:
Klinische Wochenschrift Aims and scope Submit manuscript

Summary

We studied the effect of the intravenous administration of the bisphosphonate pamidronate (AHPrBP) in 7 patients with Paget's bone disease. The medication was given in a daily dose of 20 mg for 9 days in 0.9% saline infusion over 4 hours (total dose 180 mg). Thereafter the patients received no therapy. At the end of treatment a slight but significant fall of plasma calcium (p≤0.01) was observed, but no patient displayed hypocalcemia. The urinary excretion of hydroxyproline fell below 45% of initial within 6 days of treatment. Only 3 out of 7 patients showed a decline in alkaline phosphatase activity (AP) already at the end of treatment, but after 3 to 6 months AP was below 30% of the initial value in all observed patients. After 9 months no relapse of AP was observed. Roentgenograms demonstrated dramatic improvement of bone lesions in one case. Hyperthermia occurred in 2 patients as side effect; one patient developed headache. However, treatment could be continued in all cases.

The short-term intravenous administration of pamidronate is a useful means to suppress the activity of Paget's disease and no further treatment is necessary at least for several months.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Literatur

  1. Altman RD, Johnston CC, Khairi MRA, Wellman H, Serafini AN, Sankey RR (1973) Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans). N Engl J Med 289:1379–1384

    Google Scholar 

  2. Boyce BF, Smith L, Fogelman I, Ralston S, Boyle IT (1982) Diphosphonates and inhibition of bone mineralisation. Lancet 1:964–965

    Google Scholar 

  3. Canfield R, Rosner W, Skinner J, McWhorter J, Resnick L, Feldman F, Kammerman S, Ryan K, Kunigonis M, Bohne W (1977) Diphosphonate therapy of Paget's disease of bone. J Clin Endocrinol Metab 44:96–106

    Google Scholar 

  4. Carano A, Teitelbaum SL, Konsek JD, Schlesinger PH, Blair HC (1990) Biphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest 85:456–461

    Google Scholar 

  5. Fleisch H (1985) Bisphosphonate als Therapeutika — experimentelle Untersuchungen und klinische Anwendung. Therapeutische Umschau 42:366–375

    Google Scholar 

  6. Frijlink WB, Te Weide J, Bijvoet OLM, Heynen G (1979) Treatment of Paget's disease with 3-amino-1-hydroxypropy-lidene-1,1-bisphosphonate (APD). Lancet 1:799–803

    Google Scholar 

  7. Gordon MT, Anderson DC, Sharpe PT (1990) Evidence that canine distemper but not measles virus may be involved in Paget's disease of bone. Calcif Tissue Int 46 (Suppl 2):A50 (abstract 189)

    Google Scholar 

  8. Harinck HIJ, Bijvoet OLM, Blanksma HJ, Dahlinghaus-Nienhuys PJ (1987) Efficacious management with aminobisphosphonate (APD) in Paget's disease of bone. Clin Orthop 217:79–98

    Google Scholar 

  9. Holz G, Delling G, Ziegler R (1983) Etidronsäure-Therapie bei Morbus Paget des Skelettes. Dtsch Med Wochenschr 108:1954–1958

    Google Scholar 

  10. Nagant de Deuxchaisnes C, Rombouts-Lindemans C, Huaux JP, Devogelaer JP (1982) Diphosphonates and inhibition of bone mineralisation. Lancet 2:607–608

    Google Scholar 

  11. O'Doherty DP, Bickerstaff DR, McCloskey EV, Hamdy NAT, Beneton MNC, Harris S, Mian M, Kanis JA (1990) Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate. J Bone Min Res 5:483–491

    Google Scholar 

  12. Papapoulos SE, Harinck HIJ, Bijvoet OLM, Gleed JH, Fraher LJ, O'Riordan JLH (1986) Effects of decreasing serum calcium on circulating parathyroid hormone and vitamin D metabolites in normocalcaemic and hypercalcaemic patients treated with APD. Bone Mineral 1:69–78

    Google Scholar 

  13. Scharla S, Ziegler R (1989) Bisphosphonate: Therapeutische Möglichkeiten und klinische Erfahrung. In: Neugebauer H (Hrsg) Was gibt es Neues in der Medizin. Dr. Peter Müller Verlag, Wien, S 211–222

    Google Scholar 

  14. Vega E, Gonzalez D, Ghiringhelli G, Mautalen C (1987) Intravenous aminopropylidene Bisphosphonate (APD) in the treatment of Paget's bone disease. J Bone Min Res 2:267–271

    Google Scholar 

  15. Ziegler R (Hrsg) (1982) EHDP (Ethyliden-1-hydroxy-1,1-Diphosphonat). Ein neues therapeutisches Prinzip bei Osteopathien und Calciumstoffwechsel. Urban & Schwarzenberg, München

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung Innere Med. 1 (Endokrinologie und Stoffwechsel), Medizinische Universitätsklinik Heidelberg, Heidelberg

    S. H. Scharla, A. Grauer & R. Ziegler

Authors
  1. S. H. Scharla
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Grauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Ziegler
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scharla, S.H., Grauer, A. & Ziegler, R. Therapie des Morbus Paget mit dem Bisphosphonat Pamidronat (AHPrBP, früher APD). Klin Wochenschr 69, 25–30 (1991). https://doi.org/10.1007/BF01649052

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01649052

Key words

Search

Navigation